

Jinal N Bhiman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/648038/publications.pdf>

Version: 2024-02-01

51
papers

12,944
citations

182225

30
h-index

214428

50
g-index

76
all docs

76
docs citations

76
times ranked

16095
citing authors

#	ARTICLE	IF	CITATIONS
1	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. <i>Lancet, The</i> , 2022, 399, 437-446.	6.3	818
2	T cell responses to SARS-CoV-2 spike cross-recognize Omicron. <i>Nature</i> , 2022, 603, 488-492.	13.7	430
3	Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e144-e156.	2.9	32
4	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i> , 2022, 603, 679-686.	13.7	1,210
5	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. <i>Journal of Virological Methods</i> , 2022, 302, 114471.	1.0	8
6	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
7	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
8	SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020â€“21. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 821-834.	4.6	74
9	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	84
10	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virusâ€“Infected and Uninfected Persons: A Cross-Sectional Household Survey. <i>Clinical Infectious Diseases</i> , 2022, 75, e57-e68.	2.9	11
11	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	5.8	27
12	Omicron infection enhances Delta antibody immunity in vaccinated persons. <i>Nature</i> , 2022, 607, 356-359.	13.7	66
13	Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€“CoV</sc>â€2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75.	2.8	6
14	SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicronâ€™s impact in South African population cohorts. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	36
15	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
16	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. <i>Nature Medicine</i> , 2022, 28, 1785-1790.	15.2	456
17	Sixteen novel lineages of SARS-CoV-2 in South Africa. <i>Nature Medicine</i> , 2021, 27, 440-446.	15.2	326
18	Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i> , 2021, 592, 438-443.	13.7	1,381

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. <i>Nature Medicine</i> , 2021, 27, 622-625.	15.2	984
20	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
21	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). <i>New England Journal of Medicine</i> , 2021, 384, 2161-2163.	13.9	111
22	SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. <i>Nature Microbiology</i> , 2021, 6, 821-823.	5.9	221
23	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	5.1	73
24	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. <i>Nature Communications</i> , 2021, 12, 4817.	5.8	35
25	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	2.9	131
26	SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020â€“March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 3020-3029.	2.0	78
27	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021, 374, 423-431.	6.0	144
28	A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. <i>Science Immunology</i> , 2021, 6, eabf1152.	5.6	63
29	COVID-19 testing in Africa: lessons learnt. <i>Lancet Microbe</i> , The, 2020, 1, e103-e104.	3.4	65
30	Genome Sequencing of a Severe Acute Respiratory Syndrome Coronavirus 2 Isolate Obtained from a South African Patient with Coronavirus Disease 2019. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.3	8
31	A genomics network established to respond rapidly to public health threats in South Africa. <i>Lancet Microbe</i> , The, 2020, 1, e229-e230.	3.4	46
32	Engineered immunogen binding to alum adjuvant enhances humoral immunity. <i>Nature Medicine</i> , 2020, 26, 430-440.	15.2	172
33	Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. <i>Scientific Reports</i> , 2020, 10, 6201.	1.6	22
34	Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. <i>Cell Reports</i> , 2019, 29, 1756-1766.e8.	2.9	47
35	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAbs lineage. <i>PLoS Pathogens</i> , 2019, 15, e1008005.	2.1	6
36	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	2.9	23

#	ARTICLE	IF	CITATIONS
37	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , 2018, 24, 593-599.e3.	5.1	24
38	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. <i>Nature Communications</i> , 2018, 9, 4136.	5.8	11
39	Strategies for a multi-stage neutralizing antibody-based HIV vaccine. <i>Current Opinion in Immunology</i> , 2018, 53, 143-151.	2.4	105
40	Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. <i>Immunity</i> , 2017, 46, 762-764.	6.6	3
41	Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. <i>Current HIV/AIDS Reports</i> , 2017, 14, 54-62.	1.1	18
42	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	2.1	33
43	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	2.9	45
44	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	1.5	205
45	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	15.2	215
46	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A20-A21.	0.5	1
47	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
48	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. <i>PLoS Pathogens</i> , 2013, 9, e1003738.	2.1	190
49	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. <i>Nature Medicine</i> , 2012, 18, 1688-1692.	15.2	273
50	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i> , 0, , .	13.7	61
51	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104